EVE Health Group Completes Strategic Acquisition of Nextract Pty Ltd

The latest update is out from EVE Health Group Limited ( (AU:EVE) ).

EVE Health Group Limited has completed the acquisition of Nextract Pty Ltd, a biotech company specializing in solubility-enhancing drug delivery systems. This strategic move positions EVE to expand its presence in the regulated healthcare sector, particularly targeting the erectile dysfunction and dysmenorrhea markets with innovative dosage formats. The acquisition was settled through the issuance of shares, and a $1 million placement was completed to fund Nextract’s integration and initial manufacturing scale-up. The company also announced significant board and management changes, including the appointment of Dr. Stuart Gunzburg as Chief Scientific Officer and Executive Director, and the transition of Mr. Bill Fry to a Non-Executive Director role. This acquisition and leadership restructuring are expected to accelerate EVE’s growth and enhance its market positioning.

More about EVE Health Group Limited

EVE Health Group (ASX: EVE) is an Australian-based health company focused on developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries, including Meluka Australia and Nextract, EVE delivers science-led innovations aimed at supporting consumer and practitioner health across retail, pharmacy, and clinical channels.

Average Trading Volume: 1,141,326

Technical Sentiment Signal: Sell

Current Market Cap: A$5.27M

See more data about EVE stock on TipRanks’ Stock Analysis page.